vs
CoStar Group（CSGP）与West Pharmaceutical Services（WST）财务数据对比。点击上方公司名可切换其他公司
CoStar Group的季度营收约是West Pharmaceutical Services的1.1倍（$899.9M vs $805.0M），West Pharmaceutical Services净利率更高（16.4% vs 5.2%，领先11.2%），CoStar Group同比增速更快（26.9% vs 7.5%），West Pharmaceutical Services自由现金流更多（$175.0M vs $101.3M），过去两年CoStar Group的营收复合增速更高（17.1% vs 7.6%）
CoStar Group是1987年成立的美国商业地产服务商，总部位于弗吉尼亚州阿灵顿，业务覆盖北美、欧洲地区，为商业地产行业提供信息、分析及营销解决方案，旗下运营CoStar线上数据库、新闻网站及Apartments.com、Homes.com等多个线上平台。
美国West Pharmaceutical Services是注射用药品包装及给药系统的设计和制造商，1923年成立，总部位于宾夕法尼亚州埃克斯顿。成立初期主营注射类药物包装用橡胶组件，曾为青霉素和胰岛素生产商提供符合无菌要求的配套产品。
CSGP vs WST — 直观对比
营收规模更大
CSGP
是对方的1.1倍
$805.0M
营收增速更快
CSGP
高出19.3%
7.5%
净利率更高
WST
高出11.2%
5.2%
自由现金流更多
WST
多$73.7M
$101.3M
两年增速更快
CSGP
近两年复合增速
7.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $899.9M | $805.0M |
| 净利润 | $46.5M | $132.1M |
| 毛利率 | 78.6% | 37.8% |
| 营业利润率 | 5.5% | 19.5% |
| 净利率 | 5.2% | 16.4% |
| 营收同比 | 26.9% | 7.5% |
| 净利润同比 | -22.2% | 1.5% |
| 每股收益（稀释后） | $0.12 | $1.82 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSGPWST
| Q4 25 | $899.9M | $805.0M | ||
| Q3 25 | $833.6M | $804.6M | ||
| Q2 25 | $781.3M | $766.5M | ||
| Q1 25 | $732.2M | $698.0M | ||
| Q4 24 | $709.4M | $748.8M | ||
| Q3 24 | $692.6M | $746.9M | ||
| Q2 24 | $677.8M | $702.1M | ||
| Q1 24 | $656.4M | $695.4M |
净利润CSGPWST
| Q4 25 | $46.5M | $132.1M | ||
| Q3 25 | $-30.9M | $140.0M | ||
| Q2 25 | $6.2M | $131.8M | ||
| Q1 25 | $-14.8M | $89.8M | ||
| Q4 24 | $59.8M | $130.1M | ||
| Q3 24 | $53.0M | $136.0M | ||
| Q2 24 | $19.2M | $111.3M | ||
| Q1 24 | $6.7M | $115.3M |
毛利率CSGPWST
| Q4 25 | 78.6% | 37.8% | ||
| Q3 25 | 79.3% | 36.6% | ||
| Q2 25 | 78.5% | 35.7% | ||
| Q1 25 | 79.1% | 33.2% | ||
| Q4 24 | 80.1% | 36.5% | ||
| Q3 24 | 79.7% | 35.4% | ||
| Q2 24 | 80.0% | 32.8% | ||
| Q1 24 | 78.5% | 33.1% |
营业利润率CSGPWST
| Q4 25 | 5.5% | 19.5% | ||
| Q3 25 | -6.1% | 20.8% | ||
| Q2 25 | -3.5% | 20.1% | ||
| Q1 25 | -5.8% | 15.3% | ||
| Q4 24 | 5.6% | 21.3% | ||
| Q3 24 | 3.4% | 21.6% | ||
| Q2 24 | -2.4% | 18.0% | ||
| Q1 24 | -6.5% | 17.7% |
净利率CSGPWST
| Q4 25 | 5.2% | 16.4% | ||
| Q3 25 | -3.7% | 17.4% | ||
| Q2 25 | 0.8% | 17.2% | ||
| Q1 25 | -2.0% | 12.9% | ||
| Q4 24 | 8.4% | 17.4% | ||
| Q3 24 | 7.7% | 18.2% | ||
| Q2 24 | 2.8% | 15.9% | ||
| Q1 24 | 1.0% | 16.6% |
每股收益（稀释后）CSGPWST
| Q4 25 | $0.12 | $1.82 | ||
| Q3 25 | $-0.07 | $1.92 | ||
| Q2 25 | $0.01 | $1.82 | ||
| Q1 25 | $-0.04 | $1.23 | ||
| Q4 24 | $0.14 | $1.78 | ||
| Q3 24 | $0.13 | $1.85 | ||
| Q2 24 | $0.05 | $1.51 | ||
| Q1 24 | $0.02 | $1.55 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.6B | $791.3M |
| 总债务越低越好 | $140.0M | $202.8M |
| 股东权益账面价值 | $8.3B | $3.2B |
| 总资产 | $10.5B | $4.3B |
| 负债/权益比越低杠杆越低 | 0.02× | 0.06× |
8季度趋势，按日历期对齐
现金及短期投资CSGPWST
| Q4 25 | $1.6B | $791.3M | ||
| Q3 25 | $1.9B | $628.5M | ||
| Q2 25 | $3.6B | $509.7M | ||
| Q1 25 | $3.7B | $404.2M | ||
| Q4 24 | $4.7B | $484.6M | ||
| Q3 24 | — | $490.9M | ||
| Q2 24 | — | $446.2M | ||
| Q1 24 | — | $601.8M |
总债务CSGPWST
| Q4 25 | $140.0M | $202.8M | ||
| Q3 25 | $1.0B | $202.7M | ||
| Q2 25 | $1.0B | $202.6M | ||
| Q1 25 | $1.0B | $202.6M | ||
| Q4 24 | $1.0B | $202.6M | ||
| Q3 24 | $1.0B | $202.6M | ||
| Q2 24 | $1.0B | $205.8M | ||
| Q1 24 | $1.0B | $206.2M |
股东权益CSGPWST
| Q4 25 | $8.3B | $3.2B | ||
| Q3 25 | $8.6B | $3.1B | ||
| Q2 25 | $8.6B | $2.9B | ||
| Q1 25 | $8.6B | $2.7B | ||
| Q4 24 | $7.6B | $2.7B | ||
| Q3 24 | $7.5B | $2.8B | ||
| Q2 24 | $7.4B | $2.6B | ||
| Q1 24 | $7.3B | $2.7B |
总资产CSGPWST
| Q4 25 | $10.5B | $4.3B | ||
| Q3 25 | $10.8B | $4.1B | ||
| Q2 25 | $10.5B | $4.0B | ||
| Q1 25 | $10.4B | $3.6B | ||
| Q4 24 | $9.3B | $3.6B | ||
| Q3 24 | $9.1B | $3.7B | ||
| Q2 24 | $9.1B | $3.5B | ||
| Q1 24 | $9.0B | $3.6B |
负债/权益比CSGPWST
| Q4 25 | 0.02× | 0.06× | ||
| Q3 25 | 0.12× | 0.07× | ||
| Q2 25 | 0.12× | 0.07× | ||
| Q1 25 | 0.12× | 0.08× | ||
| Q4 24 | 0.13× | 0.08× | ||
| Q3 24 | 0.13× | 0.07× | ||
| Q2 24 | 0.14× | 0.08× | ||
| Q1 24 | 0.14× | 0.08× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $162.1M | $251.1M |
| 自由现金流经营现金流 - 资本支出 | $101.3M | $175.0M |
| 自由现金流率自由现金流/营收 | 11.3% | 21.7% |
| 资本支出强度资本支出/营收 | 6.8% | 9.5% |
| 现金转化率经营现金流/净利润 | 3.49× | 1.90× |
| 过去12个月自由现金流最近4个季度 | $123.0M | $468.9M |
8季度趋势，按日历期对齐
经营现金流CSGPWST
| Q4 25 | $162.1M | $251.1M | ||
| Q3 25 | $68.2M | $197.2M | ||
| Q2 25 | $146.5M | $177.1M | ||
| Q1 25 | $53.2M | $129.4M | ||
| Q4 24 | $94.6M | $190.1M | ||
| Q3 24 | $100.3M | $180.1M | ||
| Q2 24 | $58.1M | $165.0M | ||
| Q1 24 | $139.6M | $118.2M |
自由现金流CSGPWST
| Q4 25 | $101.3M | $175.0M | ||
| Q3 25 | $-5.5M | $133.9M | ||
| Q2 25 | $27.7M | $101.9M | ||
| Q1 25 | $-500.0K | $58.1M | ||
| Q4 24 | $25.2M | $85.2M | ||
| Q3 24 | $40.2M | $98.8M | ||
| Q2 24 | $-14.7M | $64.8M | ||
| Q1 24 | $-237.1M | $27.6M |
自由现金流率CSGPWST
| Q4 25 | 11.3% | 21.7% | ||
| Q3 25 | -0.7% | 16.6% | ||
| Q2 25 | 3.5% | 13.3% | ||
| Q1 25 | -0.1% | 8.3% | ||
| Q4 24 | 3.6% | 11.4% | ||
| Q3 24 | 5.8% | 13.2% | ||
| Q2 24 | -2.2% | 9.2% | ||
| Q1 24 | -36.1% | 4.0% |
资本支出强度CSGPWST
| Q4 25 | 6.8% | 9.5% | ||
| Q3 25 | 8.8% | 7.9% | ||
| Q2 25 | 15.2% | 9.8% | ||
| Q1 25 | 7.3% | 10.2% | ||
| Q4 24 | 9.8% | 14.0% | ||
| Q3 24 | 8.7% | 10.9% | ||
| Q2 24 | 10.7% | 14.3% | ||
| Q1 24 | 57.4% | 13.0% |
现金转化率CSGPWST
| Q4 25 | 3.49× | 1.90× | ||
| Q3 25 | — | 1.41× | ||
| Q2 25 | 23.63× | 1.34× | ||
| Q1 25 | — | 1.44× | ||
| Q4 24 | 1.58× | 1.46× | ||
| Q3 24 | 1.89× | 1.32× | ||
| Q2 24 | 3.03× | 1.48× | ||
| Q1 24 | 20.84× | 1.03× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSGP
| Co Star | $503.8M | 56% |
| Other | $283.0M | 31% |
| Loop Net | $94.7M | 11% |
WST
| Proprietary Products | $661.8M | 82% |
| Contract Manufactured Products | $143.2M | 18% |
| Affiliated Entity | $3.3M | 0% |
